TrianglePembrolizumab (NCT07089992)
Pembrolizumab trial for Sarcoma (NCT07089992). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or metastatic pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, or sclerosing epithelioid fibrosarcoma/low-grade fibromyxoid sarcoma. One to three prior lines are required, stopped for progression, toxicity, or patient choice. Prior checkpoint immunotherapy is excluded.
The idea: pembrolizumab releases the PD-1 immune brake, to support immune attack. Infusions occur every six weeks, up to eight doses. Researchers measure tumor response at twelve weeks and assess safety.
This phase 2 study plans 32 patients. Robert Maki leads at Memorial Sloan Kettering in New York; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.